RxDoctor Payments Data

Rachel Sing, MD

Family Medicine · Booneville, ARNPI 1457641763

Payments from drug & device makers

$1,148in general payments, 2019–2025

Across 64 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$282
  • Exact Sciences$119
  • Lilly USA, LLC$108
  • Otsuka America Pharmaceutical, Inc.$104
  • Astellas Pharma US Inc$100
  • Amgen$98
  • plus $337 from 9 others

What the payments were for

  • Food & beverage$1,01889%
  • Education$13011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,148 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$27,412
Medicare patients
200
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$115,389
JardianceEmpagliflozin81$74,565
OzempicSemaglutide62$64,154
Breztri AerosphereBudesonide/Glycopyr/Formoterol83$60,330
RexultiBrexpiprazole34$41,456
MounjaroTirzepatide31$38,278
XareltoRivaroxaban46$37,984
LinzessLinaclotide35$26,091
TrulicityDulaglutide27$25,069
FarxigaDapagliflozin Propanediol23$23,099
Tresiba Flextouch U-200Insulin Degludec16$21,671
MyrbetriqMirabegron33$21,669
Nurtec OdtRimegepant Sulfate11$21,623
Tresiba Flextouch U-100Insulin Degludec35$19,138
Combivent RespimatIpratropium/Albuterol Sulfate24$11,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$17$137,012162 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$29$87,763124 claims
Novo NordiskOzempic$84$64,15462 claims
Lilly USA, LLCMounjaro, Trulicity$108$63,34758 claims
Otsuka America Pharmaceutical, Inc.Rexulti$104$41,45634 claims
AbbVieLinzess, Synthroid$282$30,472112 claims
Astellas Pharma US IncMyrbetriq$100$21,66933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Booneville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →